Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

⚠ Conference abstract — not peer-reviewed alzhub usefulness score 16 out of 100. Getting a diagnosis

Topic: Amyloid, tau and blood-test diagnosis

Researchers tested whether a tablet-based cognitive test (TabCAT) could substitute for traditional paper-and-pencil memory tests in people with early-onset Alzheimer's. Scores on the tablet's attention/executive tasks correlated strongly (above 0.7) with standard tests like the MMSE and MoCA, and one subtest could distinguish people with amyloid plaques from those without with good accuracy (AUC 0.82). This supports using quicker digital tools for early detection, especially in younger-onset patients who are often screened later.

Key findings

Why it matters

Researchers tested whether a tablet-based cognitive test could substitute for traditional paper-and-pencil memory tests in people with early-onset Alzheimer's and found that scores on the tablet's attention/executive tasks correlated strongly with standard tests like the MMSE and MoCA. One subtest could distinguish people with amyloid plaques from those without with good accuracy, supporting use of quicker digital tools for early detection.

Study details

Limitations

Data presented as a conference abstract/poster (AAIC 2025), not yet a full peer-reviewed paper with complete methods; cross-sectional design cannot show whether the tool predicts future decline; sample restricted to early-onset AD, so results may not generalize to typical late-onset AD.

How this study scored 16/100
How this study's score is builtJournal tier 2 of 10; Journal's citation record 0 of 4; Study design 4 of 12; Strength of evidence 3 of 5; Peer-review validation 3 of 10; How recent 4 of 5; Sample size 2 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited left out, no data; Citations per year left out, no data; Impact for its field and year left out, no data; Cited by studies here 0 of 6; Still being cited left out, no data; Senior author's track record left out, no data; Institution's track record left out, no data; Multi-centre collaboration left out, no data; Indexed in PubMed 0 of 2; Free to read left out, no data. 24 of the 66 points it could be judged on, which is 36 of 100. Raw total 36 of 100, shown as 16 because this is not a peer-reviewed research article.raw total 36 of 100capped at 16 — hatched points do not count

Conference abstract — not peer-reviewed. It scored 36 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for randomised / blinded and indexed in PubMed because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 24 of the 66 points we could judge it on, which is 36 out of 100.

ComponentPointsWhy
Journal tier 2 / 10 Tier 4 — not a peer-reviewed journal (Alzheimer's & Dementia (AAIC 2025 conference abstract))
Journal's citation record 0 / 4 Not a journal article, so the journal's record does not count
Study design 4 / 12 A snapshot of people at one point in time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 3 / 10 Conference abstract — not peer-reviewed. Journal string identifies this as a conference abstract or presentation.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 2 / 4 475 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited — / 7 No citation count (not found in OpenAlex) — left out of this score
Citations per year — / 5 No citation count or no year — left out of this score
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited — / 4 No yearly citation counts — left out of this score
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multi-centre collaboration — / 3 Institutions not listed — left out of this score
Indexed in PubMed 0 / 2 No PubMed ID and no DOI — scores zero (not stated in the record — scored 0)
Free to read — / 2 Access not recorded — left out of this score
Points 24 / 66 Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 24 of the 66 points we could judge it on is 36 out of 100.
Total 36 / 100 Capped to 16 because this is not a peer-reviewed article.

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. This record has no DOI, so the citation leaves it out. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Njamnshi, W. Y., Chiotis, K., Tsoy, E., et al. (2025). Tablet-based cognitive assessment in a multisite study of early-onset AD: association with pen-and-paper tests and PET measures of amyloid and tau. Alzheimer's & Dementia (AAIC 2025 conference abstract).

Vancouver

Njamnshi WY, Chiotis K, Tsoy E, et al. Tablet-based cognitive assessment in a multisite study of early-onset AD: association with pen-and-paper tests and PET measures of amyloid and tau. Alzheimer's & Dementia (AAIC 2025 conference abstract). 2025.

BibTeX

@article{njamnshi2025-b808c263,
  author  = {Njamnshi, W. Y. and Chiotis, K. and Tsoy, E. and others},
  title   = {{Tablet-based cognitive assessment in a multisite study of early-onset AD: association with pen-and-paper tests and PET measures of amyloid and tau}},
  journal = {Alzheimer's \& Dementia (AAIC 2025 conference abstract)},
  year    = {2025}
}

Related studies in Getting a diagnosis

Also tagged “classification”

835 studies in the library carry the topic tag “classification”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 835 tagged studies.

Similar studies

More on Getting a diagnosis

See all studies in Getting a diagnosis →